PolandPoland

USDA criticises GMO policy

29.04.2009

Warsaw/Washington – The US Department of Agriculture (USDA) has criticised the draft law on genetically modified organisms (GMOs) that Poland recently submitted to the European Commission. The rules defined in the law “will prevent planting GM crops in Poland,” according to a USDA report (GAIN report No. PL 9005) released in March. The Eastern European nation has come under especially heavy fire for the choice of the 18 experts who will set the GMO policy and approval of rules. The USDA said that it is clear that the panel will not approve a single GMO, as industry and farming experts were excluded by the Polish Environment Ministry in favor of representatives from anti-GMO lobby groups. The USDA has also criticised Poland’s plans to limit research on GM crops to closed systems, and to vote against every EU market approval application covering cultivation of GM crops. Other USDA concerns include Poland’s plans to establish GMO-free zones by naming regional inspectors who are able to prohibit GMO cultivation in specific regions for environmental protection reasons. According to the report, Poland is one of Europe’s “most active governments lobbying against the adoption of agricultural biological sciences worldwide.”

PolandPoland

07.03.2012

Polish antibody development and manufacturing specialist Mabion S.A. more than tripled its revenues in 2011 (€2.5m) compared to 2010 (€0.74m). The increase in turnover mainly resulted from stronger client demand for R&D services...

PolandPoland

01.03.2012

Polish company Bioton S.A (Warsaw) and Swiss-headquartered generics giant Actavis (Zug) have joined forces to shake up the €12bn world market for recombinant insulins and insulin analogues. At the end of January, Bioton Chairman...

PolandPoland

31.01.2012

Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes drugs. Swiss Actavis and Bioton from Warsaw announced that they have formed a joint venture company for the...

PolandPoland

10.12.2011

Krakow – Polish Selvita S.A., which offers preclinical drug development services to pharma companies, has been ranked as the No. 1 “Rising Star” of this year’s Fast50 contest. In the programme, analysts from Deloitte Technology...

PolandPoland

09.12.2011

Warsaw – Poland’s Bioton S.A. has announced it is investing €20m in a new production plant in Szczecin. The biotechnology company is planning to manufacture insulin injection devices in the facility. The project involves the...

PolandPoland

01.10.2011

Warsaw – Biotech experts want to make the development of pharmaceutical and medical innovations a priority in Poland. At the start of September, members of the Polish Technology Platform for Innovative Medicine recommended that...

PolandPoland

02.08.2011

Kraków – Selvita SA CEO Pawel Przewiezlikowski announced at the end of July that the Polish drug development and drug discovery service firm is close to achieving profitability. After bagging EUR3.7m through an IPO on Warsaw’s...

PolandPoland

12.06.2011

Warsaw – Researchers from Lodz and Poznan Universities say Poland needs to update its draft GMO law. “The national current legal situation is complicated,” Prof. Tomas Twardowski told EuroBiotechNews, stressing that while trade...

PolandPoland

12.06.2011

Krakow – Polish Selvita S.A. is going public. By May, the drug discovery specialist announced it had entered into definite agreements with investors to sell 2.7 million shares for a total of EUR3.75m, resulting in a market...

PolandPoland

11.06.2011

Szczecin/Greifswald – A team of physical chemists headed by Robert Hoylst from the Polish Academy of Science have improved a method for calculating the migration time of drugs or drug delivery devices introduced into the sol/gel...

Displaying results 1 to 10 out of 108

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-poland/article/usda-criticises-gmo-policy.html

Stock list

All quotes

TOP

  • WILEX (D)3.11 EUR288.75%
  • NOVACYT (F)5.00 EUR18.76%
  • OREXO (S)137.25 SEK11.13%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.11 EUR326.0%
  • SANTHERA (CH)67.60 CHF109.0%
  • ADDEX (CH)4.19 CHF91.3%

FLOP

  • MERCK KGAA (D)64.02 EUR-50.5%
  • VERONA PHARMA (UK)1.07 GBP-48.6%
  • THROMBOGENICS (B)8.38 EUR-48.3%

TOP

  • SANTHERA (CH)67.60 CHF3331.5%
  • GW PHARMACEUTICALS (UK)415.25 GBP765.1%
  • PHARMING (NL)0.51 EUR325.0%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)8.38 EUR-73.9%

No liability assumed, Date: 20.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events